Olr170 inhibitors are a chemical class characterized by their interaction with the Olr170 protein, a member of the olfactory receptor family. These receptors, typically found in the olfactory epithelium, are G-protein-coupled receptors (GPCRs) that play a pivotal role in detecting volatile molecules, leading to the sensation of smell. The Olr170 receptor is part of a larger family of olfactory receptors that exhibit a high degree of variability and specificity in ligand binding. Inhibitors of Olr170 are designed to bind to this receptor and impede its normal function by blocking the receptor's interaction with its natural ligands. This can involve competitive inhibition, where the inhibitor competes with the natural ligand for binding sites, or allosteric inhibition, where the inhibitor binds to a different part of the receptor, inducing conformational changes that reduce the receptor's activity.
Chemically, Olr170 inhibitors can belong to various structural classes, with their design often focused on achieving high specificity and affinity for the Olr170 receptor. The molecular frameworks of these inhibitors are often tailored to complement the unique binding pocket of the Olr170 receptor, which may involve specific hydrogen bonding, hydrophobic interactions, or ionic interactions. The design of these inhibitors might also consider the dynamic nature of the receptor, accounting for the potential conformational flexibility that GPCRs exhibit. The development and refinement of Olr170 inhibitors involve extensive structural analysis and computational modeling, often coupled with high-throughput screening techniques to identify lead compounds that exhibit the desired inhibitory properties. These compounds are then subject to further chemical modification and optimization to enhance their binding efficiency, stability, and selectivity towards the Olr170 receptor.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Lenvatinib | 417716-92-8 | sc-488530 sc-488530A sc-488530B | 5 mg 25 mg 100 mg | $182.00 $661.00 $1690.00 | 3 | |
Multi-kinase inhibitor, potentially affects angiogenesis and signaling pathways relevant to Olr170. | ||||||
MDV3100 | 915087-33-1 | sc-364354 sc-364354A | 5 mg 50 mg | $245.00 $1051.00 | 7 | |
Androgen receptor inhibitor, could influence pathways related to hormone signaling and Olr170. | ||||||
Regorafenib | 755037-03-7 | sc-477163 sc-477163A | 25 mg 50 mg | $320.00 $430.00 | 3 | |
Multi-kinase inhibitor, may impact multiple signaling pathways potentially linked to Olr170. | ||||||
AP 24534 | 943319-70-8 | sc-362710 sc-362710A | 10 mg 50 mg | $175.00 $983.00 | 2 | |
BCR-ABL tyrosine kinase inhibitor, potentially affects pathways relevant to Olr170. | ||||||
Ixazomib | 1072833-77-2 | sc-489103 sc-489103A | 10 mg 50 mg | $311.00 $719.00 | ||
Proteasome inhibitor, could impact protein degradation processes related to Olr170. | ||||||
Rucaparib | 283173-50-2 | sc-507419 | 5 mg | $150.00 | ||
PARP inhibitor, may influence DNA repair pathways potentially affecting Olr170. | ||||||
Acalabrutinib | 1420477-60-6 | sc-507392 | 250 mg | $255.00 | ||
Bruton's tyrosine kinase inhibitor, could modulate cell signaling pathways relevant to Olr170. | ||||||
Olaparib | 763113-22-0 | sc-302017 sc-302017A sc-302017B | 250 mg 500 mg 1 g | $210.00 $305.00 $495.00 | 10 | |
PARP inhibitor, potentially affects DNA repair pathways linked to Olr170. | ||||||
Abemaciclib | 1231929-97-7 | sc-507342 | 10 mg | $110.00 | ||
CDK4/6 inhibitor, might influence cell cycle regulation pathways involving Olr170. | ||||||